Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034Martin J. van den Bent, Denis Lacombe, Paul M. Clément et al.|Journal of Clinical Oncology|2007Cited by 53
PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletionMartin J. van den Bent, Pim J. French, Sara Erridge et al.|Neuro-Oncology|2019Cited by 29
2503 ORAL Erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): results from a randomized phase II trial (EORTC 26034)Martin J. van den Bent, T. Gorlia, Denis Lacombe et al.|European Journal of Cancer Supplements|2007Cited by 5